1
|
Verhaart SL, Van Herpen CM, Oosting S, Van Der Veldt A, Osanto S, Aarts MJ, Houtsma D, Peters FP, Groenewegen G, Bex A, Mulder SF, Pronk LM, Tascilar M, Hamberg P, Los M, Vreugdenhil G, Polee M, Ten Tije AJ, Haanen JBAG, van den Eertwegh AJM. Real world experience and biomarkers of nivolumab in dutch advanced renal-cell carcinoma patients. J Clin Oncol 2018. [DOI: 10.1200/jco.2018.36.15_suppl.4572] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | | | - Sjoukje Oosting
- Department of Medical Oncology, University Medical Center Groningen, Groningen, Netherlands
| | | | | | | | | | | | | | - Axel Bex
- The Netherlands Cancer Institute, Amsterdam, Netherlands
| | | | - Loes M. Pronk
- Netherlands Cancer Institute, Amsterdam, Netherlands
| | | | - Paul Hamberg
- Franciscus Gasthuis & Vllietland, Rotterdam, Netherlands
| | - Maartje Los
- St. Antonius Hospital, Nieuwegein, Netherlands
| | | | - Marco Polee
- Medical Center Leeuwarden, Leeuwarden, Netherlands
| | | | | | | | | |
Collapse
|
2
|
Punt CJA, Simkens LH, Van Rooijen J, Van de Wouw AW, Loosveld O, Creemers GJ, Hendriks MP, Los M, Van Alphen RJ, Polee M, Muller EW, Van Der Velden A, Van Voorthuizen T, Koopman M, Mol L, Kwakman JJ, van Werkhoven ED. Randomized phase 3 study of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer (mCRC): The SALTO study of the Dutch Colorectal Cancer Group. J Clin Oncol 2016. [DOI: 10.1200/jco.2016.34.15_suppl.3640] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Cornelis J. A. Punt
- Department of Medical Oncology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands
| | | | | | | | | | - Geert-Jan Creemers
- Department of Medical Oncology, Catharina Hospital, Eindhoven, Netherlands
| | | | - Maartje Los
- St. Antonius Hospital, Nieuwegein, Netherlands
| | | | - Marco Polee
- Medical Center Leeuwarden, Leeuwarden, Netherlands
| | | | | | | | - Miriam Koopman
- Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands
| | - Linda Mol
- Netherlands Comprehensive Cancer Organization, Nijmegen, Netherlands
| | | | | |
Collapse
|
3
|
Cirkel GA, Hamberg P, Sleijfer S, Loosveld O, Dercksen W, Los M, Haanen JBAG, Polee M, Berkmortel FVD, Aarts MJ, Beerepoot LV, Groenewegen G, Lolkema MP, Tascilar M, Portielje JEA, Peters FPJ, Klümpen HJ, van de Noort V, Voest EE. A randomized phase II study to compare the efficacy of upfront bi-monthly rotations between pazopanib (PAZ) and everolimus (EVE) versus sequential treatment of first-line PAZ and second-line EVE until progression in patients with metastatic clear cell renal cell cancer (ccRCC) (ROPETAR trial). J Clin Oncol 2016. [DOI: 10.1200/jco.2016.34.15_suppl.4550] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | - Paul Hamberg
- Sint Franciscus Gasthuis, Rotterdam, Netherlands
| | - Stefan Sleijfer
- Erasmus MC Cancer Institute, Department of Medical Oncology and Cancer Genomics Netherlands, Rotterdam, Netherlands
| | | | | | - Maartje Los
- St. Antonius Hospital, Nieuwegein, Netherlands
| | | | - Marco Polee
- Medical Center Leeuwarden, Leeuwarden, Netherlands
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Kroep JR, van Werkhoven E, Polee M, van Groeningen CJ, Beeker A, Erdkamp F, Weijl N, van Bochove A, Erjavec Z, Kapiteijn E, Stiggelbout AM, Nortier HWR, Gelderblom H. Randomised study of tegafur-uracil plus leucovorin versus capecitabine as first-line therapy in elderly patients with advanced colorectal cancer--TLC study. J Geriatr Oncol 2015; 6:307-15. [PMID: 26073532 DOI: 10.1016/j.jgo.2015.05.004] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2014] [Revised: 03/20/2015] [Accepted: 05/27/2015] [Indexed: 11/28/2022]
Abstract
BACKGROUND Prospective data on chemotherapy for (frail) elderly patients with advanced colorectal cancer (aCRC) are scant. UFT/leucovorin might be as effective as and less toxic than capecitabine. We firstly randomized both agents in patients >65 years with aCRC not amenable to receive combination chemotherapy. PATIENTS AND METHODS Patients were randomised between first-line oral UFT/leucovorin and capecitabine in a Dutch multicentre trial. Primarily, efficacy and toxicity were determined. Secondary, quality of life (QoL) and abbreviated common geriatric assessment (aCGA) were analysed. RESULTS Sixty-seven patients were randomised with a median age of 77 years and 96% being frail. After interim analysis it was decided to stop recruitment because of low accrual. At a median follow up of 34 months, the median progression-free survival (PFS) and overall survival (OS) were similar for both therapies, being 21 weeks (p=0.17) and 12 months (p=0.83), respectively. The overall response rates were 24% and 21%, respectively. Two patients died of possible treatment related complications in the UFT/leucovorin arm and 3 patients in the capecitabine arm. For UFT/leucovorin significantly less grade 3 or 4 hand/foot syndrome (0 vs 5) was observed. Overall, PFS was related to Charlson-comorbidity index (p=0.049), LDH (p=0.0011) and albumin (p=0.009). OS was related to LDH (p=0.0003), albumin (p=0.0001), QoLC30/CR38 (p=0.041), QoL visual analogue scale (VAS; p=0.016), and GFI (p=0.028). CONCLUSION UFT/leucovorin and capecitabine had similar efficacy and different toxicity profiles in frail elderly patients with aCRC. Baseline serum levels of albumin and LDH, Charlson-comorbidity index, GFI and QoL were prognostic for clinical outcome.
Collapse
Affiliation(s)
- Judith R Kroep
- Leiden University Medical Center, Department of Clinical Oncology, Leiden, The Netherlands
| | - Erik van Werkhoven
- The Netherlands Cancer Institute, Department of Statistics, Amsterdam, The Netherlands
| | - Marco Polee
- Department of Internal Medicine, Medical Center Leeuwarden, Leeuwarden, The Netherlands
| | | | - Aart Beeker
- Department of Internal Medicine, Spaarne Hospital, Hoofddorp, The Netherlands
| | - Frans Erdkamp
- Department of Internal Medicine, Orbis Medical Center, Sittard, The Netherlands
| | - Nir Weijl
- Department of Medical Oncology, Bronovo Hospital, The Hague, The Netherlands
| | - Aart van Bochove
- Department of Internal Medicine, Zaans Medical Centre, Zaanstad, The Netherlands
| | - Zoran Erjavec
- Department of Internal Medicine, Ommelander Hospital, Delfzijl, The Netherlands
| | - Ellen Kapiteijn
- Leiden University Medical Center, Department of Clinical Oncology, Leiden, The Netherlands
| | - Anne M Stiggelbout
- Leiden University Medical Center, Department of Medical Decision Making, Leiden, The Netherlands
| | - Hans W R Nortier
- Leiden University Medical Center, Department of Clinical Oncology, Leiden, The Netherlands
| | - Hans Gelderblom
- Leiden University Medical Center, Department of Clinical Oncology, Leiden, The Netherlands
| |
Collapse
|
5
|
Goudzwaard J, Fiets WE, van de Geijn G, Njo T, Zuetenhorst J, Birnie E, van Schaik RH, Putten MVD, Polee M, Hamberg P. Mannose-binding lectin (MBL) serum level and genotype and risk of chemotherapy-induced febrile neutropenia (FN) in patients with solid tumors. J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.15_suppl.e20653] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | | | | | - T. Njo
- Sint Franciscus Gasthuis, Rotterdam, Netherlands
| | | | - E. Birnie
- Sint Fransiscus Gasthuis, Rotterdam, Netherlands
| | | | | | - Marco Polee
- Medical Center Leeuwarden, Leeuwarden, Netherlands
| | - Paul Hamberg
- Department of Internal Medicine, Sint Franciscus Gasthuis, Rotterdam, Netherlands
| |
Collapse
|
6
|
Meulenbeld H, van Werkhoven E, Coenen J, Creemers G, Loosveld O, de Jong P, ten Tije A, Fosså S, Polee M, Gerritsen W, Dalesio O, de Wit R. Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro). Eur J Cancer 2012; 48:2993-3000. [DOI: 10.1016/j.ejca.2012.05.014] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2012] [Revised: 05/09/2012] [Accepted: 05/15/2012] [Indexed: 01/20/2023]
|
7
|
Reyners AKL, de Munck L, Erdkamp FLG, Smit WM, Hoekman K, Lalisang RI, de Graaf H, Wymenga ANM, Polee M, Hollema H, van Vugt MATM, Schaapveld M, Willemse PHB. A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the DoCaCel study. Ann Oncol 2012; 23:2896-2902. [PMID: 22689176 DOI: 10.1093/annonc/mds107] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/06/2023] Open
Abstract
BACKGROUND In ovarian cancer, cyclooxygenase-2 (COX-2) overexpression is prognostic for poor survival. We investigated the efficacy of celecoxib (C), a selective COX-2 inhibitor, added to docetaxel (Taxotere)/carboplatin (DC) in advanced ovarian cancer. PATIENTS AND METHODS In a phase II, randomized study, 400 mg celecoxib b.i.d. was added to first-line DC treatment (DCC). Celecoxib was to be continued after DC termination up to 3 years. Study end points were tolerability, progression-free survival (PFS) and overall survival (OS). RESULTS 151 of 196 eligible patients were diagnosed with stage IIIC/IV disease. Median follow-up for patients alive was 32.3 months. Celecoxib was used during a mean of 8.5 months. Twenty-three of 97 DCC patients stopped celecoxib prematurely, mainly due to skin reactions. Complete biochemical response was achieved in 51/78 DC patients (65%) versus 57/78 DCC patients (75%, not significant). In both study arms, median PFS was 14.3 months and median OS 34 months. COX-2 was expressed in 82% of 120 tumor samples retrospectively recovered. The PFS and OS of patients with intermediate/high COX-2 expression were similar to that in the other patients. CONCLUSION Celecoxib did not influence PFS and OS, but interpretation of results is hampered by premature celecoxib discontinuation.
Collapse
Affiliation(s)
- A K L Reyners
- Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen.
| | - L de Munck
- Department of Research, Comprehensive Cancer Center The Netherlands, Utrecht
| | - F L G Erdkamp
- Department of Internal Medicine, Orbis Medical Center, Sittard
| | - W M Smit
- Department of Internal Medicine, Medical Spectrum Twente, Enschede
| | - K Hoekman
- Department of Medical Oncology, VU University Medical Center, Amsterdam
| | - R I Lalisang
- Department of Medical Oncology, University Medical Center, Maastricht
| | - H de Graaf
- Department of Internal Medicine, Medical Center Leeuwarden, Leeuwarden
| | - A N M Wymenga
- Department of Internal Medicine, Medical Spectrum Twente, Enschede
| | - M Polee
- Department of Internal Medicine, Medical Center Leeuwarden, Leeuwarden
| | - H Hollema
- Department of Pathology, University of Groningen, University Medical Center Groningen, Groningen
| | - M A T M van Vugt
- Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen
| | - M Schaapveld
- Department of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - P H B Willemse
- Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen
| |
Collapse
|
8
|
Meulenbeld HJ, van Werkhoven ED, Coenen JLLM, Creemers G, Loosveld OJL, De Jong PC, Ten Tije AJ, Fossa SD, Polee M, Gerritsen WR, Dalesio O, De Wit R. Randomized phase III study of docetaxel with or without risedronate in patients with bone metastases from castration-resistant prostate cancer (CRPC): The Netherlands Prostate Study (NePro). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.4518] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
9
|
Reyners A, Smit WM, Schaapveld MS, Hoekman K, Erdkamp F, Lalisang R, Graaf H, Wymenga MA, Polee M, Willemse PH. Adding the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin in first line for stage IC-IV epithelial ovarian cancer: A randomized phase II study. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.5545] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5545 Background: Inhibition of COX-2 reduces the growth rate of tumors in vitro and COX-2 is over-expressed in ovarian cancer, so a COX-2 inhibitor might be beneficial. Methods: After debulking surgery patients (pts) with advanced epithelial ovarian cancer (FIGO IC-IV) received docetaxel 75 mg/m2 and carboplatin AUC=5 (CT) for 6–9 cycles q 3-wks and were randomized to celecoxib 400 mg BID (COX) for max three years or to control (CTR), stratified for residual tumor present in 58% vs 54%. Response rates and progression-free survival were based on CA-125 levels according to Rustin. Primary endpoints were biochemical CR (bCR)and safety, secondary progression free- (PFS) and overall survival (OS). Results: 183 of 201 pts enrolled were analyzed and baseline characteristics were well balanced between COX (n = 91) and control (CTR) arms (n = 93). Safety: Docetaxel and carboplatin was given full dose in 89% vs 84% pts and creatinine clearance remained stable vs baseline in both arms (96% vs 97% at Cycle 6). Toxicity grade 3–4 (COX vs CTR) was neutropenia in 26 vs 32, febrile neutropenia 12 vs 12, N/V 6 vs 5, allergy 7 vs 0 pts. Neurosensory grade 2–3 was less in COX (4 vs 13 pts, p< 0.05). Efficacy: Median duration of COX treatment was 6 months and 60% completed the combination with six or more cycles of CT. At a median follow-up of 20 months, CA-125 normalized (bCR) in COX 55/74 (74%) and CTR 49/74 (66%) pts with elevated baseline levels (n.s.). Median PFS was 17.4 vs 14.5 months (n.s.) and median survival 34.2 vs 34.7 months (n.s.). Conclusions: Celecoxib added to docetaxel/carboplatin in epithelial ovarian cancer had no effect on creatinine clearance, CA-125 response, PFS or OS. Celecoxib during CT was associated with allergic skin reactions but less neurotoxicity. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- A. Reyners
- Medisch Spectrum Twente, Enschede, Netherlands; IKNO, Groningen, Netherlands; VUMC, Amsterdam, Netherlands; Maaslandziekenhuis, Sittard, Netherlands; AMC, Maastricht, Netherlands; Medisch Centrum, Leeuwarden, Netherlands; Medisch Centrum, Leeuwarden, Netherlands; University Medical Center Groningen, Groningen, Netherlands
| | - W. M. Smit
- Medisch Spectrum Twente, Enschede, Netherlands; IKNO, Groningen, Netherlands; VUMC, Amsterdam, Netherlands; Maaslandziekenhuis, Sittard, Netherlands; AMC, Maastricht, Netherlands; Medisch Centrum, Leeuwarden, Netherlands; Medisch Centrum, Leeuwarden, Netherlands; University Medical Center Groningen, Groningen, Netherlands
| | - M. S. Schaapveld
- Medisch Spectrum Twente, Enschede, Netherlands; IKNO, Groningen, Netherlands; VUMC, Amsterdam, Netherlands; Maaslandziekenhuis, Sittard, Netherlands; AMC, Maastricht, Netherlands; Medisch Centrum, Leeuwarden, Netherlands; Medisch Centrum, Leeuwarden, Netherlands; University Medical Center Groningen, Groningen, Netherlands
| | - K. Hoekman
- Medisch Spectrum Twente, Enschede, Netherlands; IKNO, Groningen, Netherlands; VUMC, Amsterdam, Netherlands; Maaslandziekenhuis, Sittard, Netherlands; AMC, Maastricht, Netherlands; Medisch Centrum, Leeuwarden, Netherlands; Medisch Centrum, Leeuwarden, Netherlands; University Medical Center Groningen, Groningen, Netherlands
| | - F. Erdkamp
- Medisch Spectrum Twente, Enschede, Netherlands; IKNO, Groningen, Netherlands; VUMC, Amsterdam, Netherlands; Maaslandziekenhuis, Sittard, Netherlands; AMC, Maastricht, Netherlands; Medisch Centrum, Leeuwarden, Netherlands; Medisch Centrum, Leeuwarden, Netherlands; University Medical Center Groningen, Groningen, Netherlands
| | - R. Lalisang
- Medisch Spectrum Twente, Enschede, Netherlands; IKNO, Groningen, Netherlands; VUMC, Amsterdam, Netherlands; Maaslandziekenhuis, Sittard, Netherlands; AMC, Maastricht, Netherlands; Medisch Centrum, Leeuwarden, Netherlands; Medisch Centrum, Leeuwarden, Netherlands; University Medical Center Groningen, Groningen, Netherlands
| | - H. Graaf
- Medisch Spectrum Twente, Enschede, Netherlands; IKNO, Groningen, Netherlands; VUMC, Amsterdam, Netherlands; Maaslandziekenhuis, Sittard, Netherlands; AMC, Maastricht, Netherlands; Medisch Centrum, Leeuwarden, Netherlands; Medisch Centrum, Leeuwarden, Netherlands; University Medical Center Groningen, Groningen, Netherlands
| | - M. A. Wymenga
- Medisch Spectrum Twente, Enschede, Netherlands; IKNO, Groningen, Netherlands; VUMC, Amsterdam, Netherlands; Maaslandziekenhuis, Sittard, Netherlands; AMC, Maastricht, Netherlands; Medisch Centrum, Leeuwarden, Netherlands; Medisch Centrum, Leeuwarden, Netherlands; University Medical Center Groningen, Groningen, Netherlands
| | - M. Polee
- Medisch Spectrum Twente, Enschede, Netherlands; IKNO, Groningen, Netherlands; VUMC, Amsterdam, Netherlands; Maaslandziekenhuis, Sittard, Netherlands; AMC, Maastricht, Netherlands; Medisch Centrum, Leeuwarden, Netherlands; Medisch Centrum, Leeuwarden, Netherlands; University Medical Center Groningen, Groningen, Netherlands
| | - P. H. Willemse
- Medisch Spectrum Twente, Enschede, Netherlands; IKNO, Groningen, Netherlands; VUMC, Amsterdam, Netherlands; Maaslandziekenhuis, Sittard, Netherlands; AMC, Maastricht, Netherlands; Medisch Centrum, Leeuwarden, Netherlands; Medisch Centrum, Leeuwarden, Netherlands; University Medical Center Groningen, Groningen, Netherlands
| |
Collapse
|
10
|
Tesselaar ME, Luelmo S, Polee M, van Bochove A, Ouwerkerk J, Pruijt H, Sleeboom H. Randomized, phase II study comparing cisplatin and high-dose 5-fluorouracil/leucovorin with paclitaxel and high-dose 5-fluorouracil/leucovorin in patients with advanced gastric cancer and adenocarcinomas of the gastroesophageal junction. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.4567] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|